Rhythm Pharmaceuticals (RYTM) Net Cash Flow (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Net Cash Flow data on file, last reported at $7.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 55.97% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was -$44.4 million, a 184.33% decrease from a year earlier, with the FY2025 full-year figure at -$34.9 million, down 219.44% from the prior year.
• Net Cash Flow for Q1 2026 stood at $7.5 million, up from $2.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for RYTM reached as high as $108.5 million in Q2 2024 and fell as low as -$113.5 million in Q3 2024.
• Historically, Net Cash Flow has averaged $162764.7 across 5 years, with a median of $6.1 million in 2023.
• Across the five-year window, Net Cash Flow slumped 193.85% in 2023 and surged 1668.92% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$57.4 million in 2022, then surged by 92.48% to -$4.3 million in 2023, then surged by 1040.74% to $40.6 million in 2024, then plunged by 95.05% to $2.0 million in 2025, then surged by 271.49% to $7.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $7.5 million in Q1 2026, $2.0 million in Q4 2025, and -$83.7 million in Q3 2025.